HER2 Support Group Forums - View Single Post - at ASCO meeting heard Dr. Robert Carlson of Stanford

schoonder · 06-06-2011, 06:22 AM

"Here's to hoping for some day in the not too distant future when her2+ patients won't have to undergo nontargeted treatment"

Failure to account for "ALL" non-targeted treatment was reason for FDA refusal to even look at data that showed what T-DM1 could do for 3rd-line HER2+ MBC patients. Need to see those regulations upgraded to reflect a more individualistic health care approach and hopefully FDA Congressional Oversight Committee is busy getting the ball rolling.

06-06-2011, 06:22 AM	#3
schoonder Senior Member Join Date: Jul 2008 Posts: 186	Re: at ASCO meeting heard Dr. Robert Carlson of Stanford "Here's to hoping for some day in the not too distant future when her2+ patients won't have to undergo nontargeted treatment" Failure to account for "ALL" non-targeted treatment was reason for FDA refusal to even look at data that showed what T-DM1 could do for 3rd-line HER2+ MBC patients. Need to see those regulations upgraded to reflect a more individualistic health care approach and hopefully FDA Congressional Oversight Committee is busy getting the ball rolling.